Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
Semaglutide and other GLP-1 medications are designed to be injected just under the skin in the fatty tissue layer, a method called subcutaneous injection
Users often start with an initiation dose of 0.25 mg, then scale up in four-weekly increments until they reach the maintenance dose of 2.4 mg per week
doi: 10.1111/dom.14725
This literature review was conducted following the PICO Framework, with details available in Supplementary material 1
How Do New GLP-1 Drugs Impact Businesses' Ability to Provide Them to Employees
